For nearly forty years the Italian territorial pharmaceutical system rested on a structural equilibrium: one independent pharmacy for every 3,000-3,500 inhabitants approximately, under a closed-ownership market (reserved to graduate pharmacists), an intermediate distribution with 60+ regional and national wholesalers, a value chain where each actor had a regulated margin and a defined service geography. The model had its flaws — low dynamism, inflexible prices, scarce innovation — but it held.
A note for non-Italian readers: this article describes a structural transformation of the Italian pharmacy retail market specifically — closed pharmacy ownership, regulated margins, and the DD/DPC (direct distribution / distribution on behalf of National Health Service) anomaly are Italian specifics. The chain consolidation dynamics observed here are however part of a broader European pattern (UK, Germany, Poland, Czech Republic have moved earlier and further in the same direction).
Since 2017, with the partial liberalisation allowing capital companies to enter pharmacy ownership, and from the first acquisition wave 2018-2022 consolidating Italian chains, the equilibrium has begun to change. Today, in 2026, Italian pharmacy chains control a growing share of pharmaceutical retail, and — central point of this article — most chains of certain size are building proprietary distribution centres (CeDi — Centri di Distribuzione), effectively disintermediating traditional intermediate distribution.
This article reconstructs the current map of Italian pharmacy chains, describes the proprietary CeDi mechanism, integrates the picture with the distribution on behalf of NHS (DPC — Distribuzione Per Conto) dynamic that is another structural disintermediation vector, and addresses the concrete question: what operationally remains for regional intermediate distributors left alone on the territory?
The map of Italian pharmacy chains
The main capital chains operating in Italy in 2026 are four, with different sizes and models.
Hippocrates Holding (Antin Infrastructure Partners-owned). It’s the capital-owned chain that has grown most rapidly in the last three years in Italy. Latest market estimates (sector sources) speak of over 300 integrated pharmacies on Italian territory, predominantly in centre-north, with a focus on metropolitan areas and provincial capitals. Hippocrates typically works with a model of progressive acquisition of independent pharmacies plus a “soft” affiliation network (non-controlled pharmacies but with commercial agreements).
Dr.Max (Penta Investments group). Entered Italy in 2022-2023, applied the model already operating in Czech Republic, Poland and Slovakia: aggressive acquisition of existing pharmacies, rapid operational integration, unified brand. Italian pharmacies under Dr.Max flag in 2026 are estimated in several hundreds but the precise figure is continuously evolving. The communicated expansion plan is ambitious.
LloydsFarmacia (historically Admenta Italia, McKesson/Walgreens group). It’s the longest-standing Italian chain, present on the territory since the 2000s. After the McKesson sale in 2022 and subsequent ownership evolution, the Italian network has stabilised around 280 pharmacies, with widespread presence but with higher shares in some Centre-North regions.
Apoteca Natura / Aboca. Different model from the previous three: it’s not a capital chain but a consortium/network of affiliated independent pharmacies sharing brand, communication and product policies (with focus on natural, supplements, homeopathy). Number of affiliated pharmacies in Italy: over 1,000. The relevance for DIF is different — Apoteca Natura doesn’t replace intermediate distribution with a proprietary CeDi, but can centralise purchases of some product lines and create alternative flows.
To these add municipal / consortium chains (Municipality-owned pharmacies federating in purchase and management consortia) and regional mini-networks under formation. The picture is continuously evolving: each month sector publications (Pharmacy Scanner, Farmacista33, Rifday, Farmacia News) report new acquisitions and divestments.
How many pharmacies are already under chain control?
Estimates vary by definition (what is considered “under chain control”: only total acquisitions, or also affiliations with tight commercial agreements?). In strict sense (capital ownership), in 2026 it’s approximately 1,000-1,500 pharmacies out of a total of approximately 19,500-20,000 Italian pharmacies, or 5-8% of the total. In broad sense (acquisitions plus affiliations with significant commercial agreements), the figure rises to 15-20% of the total.
The growth rate is approximately +1-2% per year on total incidence. Consolidation is therefore real but gradual: Italy structurally remains much more fragmented than countries like UK, Germany, Poland or Czech Republic, where chains control double-digit percentages of retail.
For intermediate distribution, the crucial point is where chain pharmacies are geographically concentrated. Typically:
- Metropolitan areas (Milan, Rome, Turin, Bologna, Naples, Genoa): chain concentration 12-25% of local retail
- Medium-large provincial capitals: concentration 8-15%
- Medium and small towns: concentration typically below 3-5%
- Rural and inland areas: concentration close to zero
This geographic concentration explains an important fact: the chain consolidation effect on DIF is not uniform. An intermediate distributor active predominantly in urban areas and provincial capitals is significantly exposed; a distributor serving deep province or rural areas is little or not at all exposed. Survival strategies of the two profiles are different.
The proprietary CeDi mechanism: how it works
A pharmacy chain of certain size (above 50-100 integrated pharmacies) can economically build or acquire a proprietary distribution centre (CeDi). The resulting operational model:
The CeDi buys directly from manufacturers the highest-rotation drugs (top volume SKUs, low-price generics, commercially strategic products) bypassing intermediate distribution.
The CeDi supplies network pharmacies with frequency optimised for that network (typically daily or twice-daily for urban pharmacies, weekly for peripheral ones), in some cases with proprietary fleets and in others relying on third-party logistics operators.
Residual intermediate distribution is used by the chain for products not passing through the CeDi: stockouts, urgencies, controlled substances requiring special procedures, very low-rotation products not justifying centralised stocking, specialty products with specific transport requirements (tight cold chain, critical time slot).
The result for traditional DIF is that the most profitable flows of network pharmacies go to the chain’s CeDi, while DIF retains marginal flows, highly fragmented, with low rotation. Operationally, the delivery pattern from DIF to a chain pharmacy changes profoundly: fewer parcels per delivery, lower frequency, mix more fragmented toward urgencies and specialty.
For pharmacy-by-pharmacy cost-to-serve, a chain pharmacy is structurally less profitable than an equivalent independent pharmacy, even before fragmentation manifests operationally. The intermediate distributor that has in portfolio pharmacies recently acquired by chains may experience a progressive drop in average basket per delivery (even 30-50%) in the 12-18 months following acquisition.
DPC: the other disintermediation vector
Distribution on behalf of NHS (DPC) is a uniquely Italian anomaly deserving a dedicated section, because it combines with the CeDi phenomenon in not-always-evident ways. In the DPC model:
- The local health authority (ASL — Azienda Sanitaria Locale) buys directly from pharmaceutical manufacturers drugs of certain categories (typically high-cost drugs, transition hospital drugs, specific drugs for chronic conditions)
- Drugs purchased by ASLs are distributed to the patient through the territorial pharmacy, which performs a logistic-administrative role (delivery to patient, dispensing, registration)
- The intermediate wholesaler may be involved in the logistics of ASL → pharmacy delivery, but with a reduced margin (typically €1-3 per pack, not percentage on the drug’s price)
The share of drugs passing through DPC regime in Italy is significant: market estimates place it at approximately 30% of the value of NHS pharmaceutical spending, against an EU average around 5%. The difference is structural: the Italian system has used DPC as a healthcare-spending containment lever, and reversal is now difficult for budget sustainability reasons.
ADF (Italian Pharmaceutical Distributors Association), representing 35 companies and over 60% of Italian wholesale revenue, recurrently defines DD/DPC as “Italian anomaly in Europe” in its press releases. For the intermediate distributor, DPC is not complete disintermediation (a logistic role remains) but is margin disintermediation: the standard percentage margin (3.65% or 3% post-TAR ruling) does not apply, and the fixed per-pack one (€1-3) is significantly lower.
The combined CeDi chains + DPC effect is particularly strong on chain pharmacies in metropolitan areas: a growing share of their revenue (both in value and in volume) passes through flows bypassing the standard wholesale percentage margin. For the intermediate distributor serving those pharmacies, it’s a double compression.
What operationally remains for the intermediate distributor
Given these dynamics, the question weighing on strategic choices of a regional intermediate distributor is: what operational space remains? Four directions seen on the market.
Direction 1 — Premium service on delivery times. Independent pharmacies — the majority of Italian retail, and those untouched by consolidation — remain served almost exclusively by DIF. The service promise is the main differentiator. Intermediate distributors maintaining 2-3 hour order-to-delivery averages (vs the 12-hour regulatory baseline) have a strong commercial argument toward independents, who evaluate DIF mainly on times and execution reliability, not on price (regulated).
Direction 2 — Vertical specialisation in less-regulated segments. Veterinary (~€700M Italian market, in stable growth), parapharmacy, dermocosmetics, supplements, medical devices. On these segments margin is not law-fixed but negotiated (typical 8-15%), the market grows 4-6% annually, chains are less present. A DIF rebalancing its mix toward these segments recovers structural profitability.
Direction 3 — Premium cold chain and specialty. Managing product lines at tight thermal constraint (-20°C for biologics, some oncologicals), at tight documentary integrity (AIFA audit for advanced ATMP therapies), or at absolute urgency (chemotherapy agents dispensed intraday) creates entry barriers that chain CeDis struggle to replicate. It’s a niche segment but at higher profitability.
Direction 4 — Value-added services to pharmacies. Pre-orders (DIF prepares for shipment on pharmacist’s pre-order), fast shuttle (sub-hour deliveries for critical orders), value returns management (recovery of resaleable items before ASSINDE disposal), IT and marketing support in white label. They are additional contractual packages producing margin not on drugs but on logistic-administrative service.
None of these is a shortcut. They require investments, process redesign, staff training. But it’s the only strategic space open against the compression of regulated market + chain consolidation + DPC.
The effect on DIF EBITDA
The cumulative effect of chains + DPC on sector profitability is significant. Sector estimates (ADF sources, market analyses) quantify it in 0.3-0.7 percentage points of structural EBITDA erosion on DIF in the medium term — not in one year but on a 3-5 year horizon. On a starting base of 1.5% segment average EBITDA (Polimi 2025 data), it’s an erosion taking a growing share of operators below the sustainability threshold.
Sector consolidation — the ~60 Italian wholesalers have halved in the last 20 years — is the structural response to this pressure. It’s expected to continue: those not recovering EBITDA through the four operational directions above, and those without sufficient scale to absorb the pressure, are candidates to be objects of M&A operations or market exits.
Against this backdrop, the birth of QFarma in April 2025 — cooperative newco controlled 51% by CEF and 49% by former UNICO cooperatives, with €2.5 billion aggregated revenue and 12,000 pharmacies served — is the most visible consolidation of the last cycle. A year later, the effect on competitive geography is showing: independent regional distributors left alone on the territory have fewer purchase alternatives, less negotiating leverage with manufacturers, and more direct competitive pressure from the new cooperative pole.
Frequently asked questions
How many Italian pharmacies are chain-owned in 2026?
In strict sense (capital ownership, complete operational integration), approximately 1,000-1,500 pharmacies out of 19,500-20,000 total (5-8%). In broad sense (including affiliation agreements and networks), 15-20% of the total. Growth is approximately +1-2% per year on total incidence.
Do pharmacy chains have proprietary CeDis for all flows?
No. Typically chains manage via proprietary CeDi the highest-rotation flows and commercially strategic products. For the rest (urgencies, controlled substances, specialty cold chain, stockouts, low-rotation products) they continue to use intermediate distribution. The percentage of volume passing through CeDi vs DIF varies significantly by chain: some are around 60% via CeDi, others close to 90%.
Is DPC the same thing as direct distribution?
No, they are two distinct models. Direct distribution (DD): the manufacturer delivers directly to local health authorities/hospitals, completely bypassing DIF. Distribution on behalf of NHS (DPC): the local health authority purchases, the pharmacy distributes to the patient, and the wholesaler may be involved as logistics with reduced fixed margin. Both models erode the distributor’s standard percentage margin, but with different operational dynamics. Combined, they represent approximately 30% of Italian NHS pharmaceutical spending value.
Can a regional intermediate distributor “avoid” chain pharmacies?
Hardly selectively. Chain pharmacies are predominantly located in the same areas where the independents the distributor wants to serve are also present, and they are part of the same service territory. The realistic strategy is not to avoid them but to understand that their cost-to-serve is structurally different (higher at equal basket, because they receive from DIF mainly fragmented residual flows) and to dimension service accordingly. The margin calculator allows modelling the dynamic.
Are there intermediate distributors specialised in serving chains?
Yes, some distributors have developed structured commercial agreements with pharmacy chains to provide additional logistics services compared to their CeDi (sub-hour urgencies, controlled substances management, tight cold chain). It’s a tailored B2B model that works if the chain is large enough to justify dedicated service. For medium-sized regional distributors, it’s rarely feasible.
In summary
The consolidation of Italian pharmaceutical retail through capital chains — Hippocrates, Dr.Max, LloydsFarmacia, plus several networks and mini-chains — is a structural dynamic changing the competitive geography of intermediate distribution. In 2026, chain pharmacies represent 5-8% of the Italian total in strict sense, 15-20% in broad sense, with 12-25% concentration in metropolitan areas and typically below 5% in rural areas.
The operational point is that chains of certain size build proprietary CeDis disintermediating traditional DIF for highest-rotation flows, leaving DIF with highly fragmented residual flows. The pattern combines with DPC (distribution on behalf of NHS) representing in Italy approximately 30% of NHS pharmaceutical spending value — an anomaly versus the ~5% EU average that ADF recurrently calls “Italian anomaly in Europe”.
The cumulative DIF EBITDA effect is estimated at 0.3-0.7 percentage points of structural erosion on a 3-5 year horizon, on a starting base of 1.5% average EBITDA. On distributors already structurally under pressure, it’s a significant compression.
The four survival directions for independent regional distributors — premium service on delivery times, vertical specialisation in less-regulated segments, cold chain and specialty, value-added services to pharmacies — exist and produce margin, but require investments and strategic redesign. The progressive consolidation of the sector (the 60 Italian wholesalers halved in the last 20 years) is the structural response of those unable to pursue them.
If you are an intermediate distributor evaluating how to reposition your service mix in a market with expanding chains and DPC, talk to our team. Three months of portfolio data are enough to identify route areas where disintermediation is eroding profitability and areas where recovery space exists.